In 1982, Mulliken and Glowacki classificated @entity455 in two biological groups with different treatment, evolution and prognosis: Haemangiomas and @entity1462 . We have seen 230 @entity1 , 145 with haemangiomas and 85 with @entity1462 (74 with low flow and 11 with high flow). We have reviewed clinical, evolutive and ecographic findings. Depending on the type and localization of the lesion, we completed the study with CT, MRI and angiography. Among all the @entity1 with haemangiomas; 45 were treated with local or systemic @entity230 because of @entity548 , @entity1066 or affection in functional areas. In two more, we used interferon alfa 2a because of Kassabach-Merritt Syndrome. 23 were operated on with good aesthetic results. @entity1 with @entity1462 were managed with embolization, sclerotherapy, surgical approach or conservatively. @entity600 were treated with lasertherapy. We emphasize in correct classification of @entity455 prior to start diagnosis, treatment or parents information.

[Hemangiomas and XXXX . Review and update].

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity455 :: ('MESH:D014652', 'Disease') :: ['congenital vascular lesions', 'vascular lesions'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulceration'] @entity600 :: ('MESH:D000014', 'Disease') :: ['Capillary malformations'] @entity230 :: ('MESH:D013256', 'Chemical') :: ['steroids'] @entity1462 :: ('MESH:D054079', 'Disease') :: ['vascular malformations', 'Vascular malformations']
@entity1462 :: (MESH:D054079,Disease) :: ['vascular malformations']
